- Home
- VBF vs PLX Comparison
VBF vs PLX Comparison
Compare VBF & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VBF | PLX |
|---|---|---|
| Founded | N/A | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 169.8M | 182.9M |
| IPO Year | 1995 | 1996 |
Fundamental Metrics
Financial Performance| Metric | VBF | PLX |
|---|---|---|
| Price | $14.48 | $2.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 58.2K | ★ 796.1K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $52,744,000.00 |
| Revenue This Year | N/A | $36.81 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.85 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.44 | $1.60 |
| 52 Week High | $15.98 | $3.19 |
Technical Indicators
Market Signals| Indicator | VBF | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 26.41 | 67.52 |
| Support Level | N/A | $2.59 |
| Resistance Level | $15.21 | $3.03 |
| Average True Range (ATR) | 0.11 | 0.09 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 5.07 | 96.20 |
Price Performance
Historical ComparisonAbout VBF Invesco Bond Fund
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.